SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q/A
(Amendment No. 1)
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1996
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to ____________
Commission file number 1-10451
NORTH AMERICAN VACCINE, INC.
----------------------------
(Exact name of registrant as specified in its charter)
Canada 98-0121241
------ ----------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
12103 Indian Creek Court, Beltsville, Maryland 20705
- ---------------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (301) 419-8400
- --------------------------------------------------------------------------------
(Former name, former address and former fiscal year, if changed since last
report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No__
Indicate the number of shares outstanding of each of the registrant's classes of
common stock, as of the latest practicable date.
Common Stock, no par value, outstanding as of November 11, 1996 -- 31,258,833
shares
<PAGE>
PART II. OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
--------
Exhibit No. Description
----------- -----------
10.32 Stock Purchase Agreement dated October 11,
1996 between Abbott Laboratories ("Abbott")
and the Company.
10.33 Assets Purchase Agreement dated October 17,
1996, among the Company, Cephalon Property
Management, Inc. and Cephalon, Inc.
(confidential treatment has been requested
for portions of this exhibit).
27 Financial Data Schedule.
(b) Reports on Form 8-K
On August 16, 1996, the Company filed with the Securities and
Exchange Commission a Current Report on Form 8-K under Item 5
reporting the Agreement in principle between the Company and
Abbott to market the Company's diphtheria, tetanus and
acellular pertussis (DTaP) vaccine.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused Amendment No. 1 to this report to be signed on
its behalf by the undersigned thereunto duly authorized.
NORTH AMERICAN VACCINE, INC.
(Registrant)
By: /s/ Sharon Mates
--------------------------
Sharon Mates, Ph.D.
President
By: /s/ Lawrence J. Hineline
--------------------------
Lawrence J. Hineline
Vice President - Finance
Date: May 27, 1997
